These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20339136)

  • 1. New studies support case for bisphosphonates as possible chemopreventive agent.
    Schmidt C
    J Natl Cancer Inst; 2010 Apr; 102(7):453-5. PubMed ID: 20339136
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
    Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
    Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteonecrosis of the mandible induced by intravenous bisphosphonates in oncological patients].
    Carvalho A; Amaral Mendes R; Carvalho D; Carvalho JF
    Acta Med Port; 2008; 21(5):505-10. PubMed ID: 19187694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review.
    Tsai WS; Haghighi K; Placa SJ
    Gen Dent; 2006; 54(3):215-9; quiz 220-2. PubMed ID: 16776417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for the prevention of breast cancer.
    Greenspan EM
    Am J Med; 1996 Jun; 100(6):665. PubMed ID: 8678089
    [No Abstract]   [Full Text] [Related]  

  • 8. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
    Van Poznak C
    Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-related osteonecrosis of the jaws (ONJ): a report of two cases.
    Pongchaiyakul C; Auraiwan K; Kotruchin P; Kularbkaew C
    J Med Assoc Thai; 2007 Nov; 90(11):2494-8. PubMed ID: 18181340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw.
    Reilly MM; Moore S
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):39-41. PubMed ID: 18431898
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
    Leite AF; Figueiredo PT; Melo NS; Acevedo AC; Cavalcanti MG; Paula LM; Paula AP; Guerra EN
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):14-21. PubMed ID: 16831667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 15. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
    Migliorati CA; Schubert MM; Peterson DE; Seneda LM
    Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 17. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis].
    Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
    Jimenez-Soriano Y; Bagan JV
    Med Oral Patol Oral Cir Bucal; 2005 Jul; 10 Suppl 2():E88-91. PubMed ID: 15995577
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.